NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form? ...

NEW YORK, April 7, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2025.So what: If you purchased Merck securities during the Class Period you ma ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the company's expected revenue from Gardasil sales by 2030 [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Merck's management provided investors with optimistic forecasts, claiming expected revenue of $11 billion from Gardasil sales by 2030, driven by successful consumer activation and education efforts [3]. - The truth emerged on February 4, 2025, when Merck announced it would not achieve the projected $11 billion in sales, ceasing shipments of Gardasil to China to reduce inventory due to lower-than-expected demand [3]. - Following this announcement, Merck's stock price fell from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, marking a decline of over 9% in one day [3]. Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about Gardasil's expected revenue, which has led to significant stock price declines [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, driven by consumer activation and education efforts [1]. - On February 4, 2025, Merck announced it would not achieve the projected $11 billion in sales, ceasing shipments to China to reduce inventory due to lower-than-expected demand, resulting in a stock price drop from $99.79 to $90.74, a decline of over 9% in one day [1]. Group 2: Class Action Details - Shareholders who purchased MRK shares during the class period from February 3, 2022, to February 3, 2025, are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].

Group 1 - Merck has an average brokerage recommendation (ABR) of 1.67, indicating a consensus between Strong Buy and Buy, based on recommendations from 24 brokerage firms, with 66.7% of these being Strong Buy [2][4] - The reliability of brokerage recommendations is questioned, as studies suggest they have little success in guiding investors towards stocks with significant price appreciation potential [4][9] - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, often issuing five "Strong Buy" recommendations for every "Strong Sell" [5][9] Group 2 - The Zacks Rank, a proprietary stock rating tool, categorizes stocks from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) and is based on earnings estimate revisions, which correlate strongly with near-term stock price movements [7][10] - The Zacks Rank is more timely and reliable than the ABR, as it reflects constant revisions of earnings estimates by brokerage analysts, while the ABR may not be up-to-date [11] - For Merck, the Zacks Consensus Estimate for the current year remains unchanged at $9.01, leading to a Zacks Rank 3 (Hold), suggesting caution despite the Buy-equivalent ABR [12][13]

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud that affected investors between February 3, 2022, and February 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for Merck investors who were impacted by misleading information regarding expected revenue of $11 billion from Gardasil sales by 2030 [2]. - Defendants expressed confidence in Merck's ability to drive demand for Gardasil through consumer education efforts, which led to optimistic forecasts for its growth in China [2]. - On February 4, 2025, Merck announced it would not meet the projected $11 billion in sales due to ceasing shipments to China, resulting in a significant stock price drop from $99.79 to $90.74, a decline of over 9% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=139441&from=3 NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: NEXT STEPS FOR SHAREHOLDERS: On ...

NEW YORK, March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). CONTACT US HERE: Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: February 3, 2022 to February 3, 2025 ALLEGATIONS: According to the complaint, defendants provided investors with ma ...

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. for alleged securities fraud affecting investors between February 3, 2022, and February 3, 2025 [1][2] Summary by Sections Class Action Details - The lawsuit aims to recover losses for Merck investors who were impacted by the alleged fraud during the specified period [1] - The complaint highlights that Merck had projected $11 billion in revenue from Gardasil sales by 2030, supported by optimistic forecasts regarding consumer demand and vaccination efforts in China [2] Recent Developments - On February 4, 2025, Merck announced it would not meet the previously forecasted $11 billion in Gardasil sales by 2030, citing a halt in shipments to China to reduce inventory due to lower-than-expected demand [2] - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, marking a decline of over 9% in one day [2] Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Merck & Co., Inc. is facing a class action lawsuit from investors due to a significant drop in stock price following the company's announcement that it would not meet its projected $11 billion revenue from Gardasil sales by 2030 [1][4]. Group 1: Class Action Details - The class action represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025, with a deadline to file a lead plaintiff motion by April 14, 2025 [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Financial Projections and Impact - The complaint highlights that Merck had projected $11 billion in revenue from Gardasil sales by 2030, supported by optimistic forecasts regarding demand in China [3]. - On February 4, 2025, Merck announced it would halt Gardasil shipments to China, leading to a stock price drop from $99.79 to $90.74 per share, a decline of over 9% in one day [4].